肝脏局灶性病变的超声造影现状:SonoVue与Sonazoid的应用对比  

Current status of contrast-enhanced ultrasound in focal liver lesions:application of SonoVue versus Sonazoid

作　　者：冯林林 刘慧 李明星 侯超 FENG Linlin;LIU Hui;LI Mingxing;HOU Chao(Department of Medical Imaging,Southwest Medical University,Luzhou 646000,China;Department of Ultrasound,the Affiliated Hospital of Southwest Medical University,Luzhou 646000,China)

机构地区：[1]西南医科大学医学影像系,四川泸州646000 [2]西南医科大学附属医院超声医学科,四川泸州646000

出　　处：《分子影像学杂志》2023年第5期942-947,共6页Journal of Molecular Imaging

基　　金：四川省医学会项目(Q21089);四川省大学生创新创业项目(S202310632255)。

摘　　要：超声造影对肝脏占位性病变的诊断能力与CT和MRI相当。目前,SonoVue和Sonazoid是两种常用造影剂,前者是纯血池造影剂,后者在肝脏三血管相的基础上增加了Kupffer相,但二者在肝脏占位性病变的表现的超声造影表现及应用价值是否相同目前尚未见系统报道。本文从SonoVue和Sonazoid的理化性质、二者在肝脏良恶性占位性病变的诊断与鉴别诊断价值、引导介入治疗及安全性能等方面的应用进展进行综述。Contrast-enhanced ultrasound is comparable to CT and MRI in its ability to diagnose focal liver lesions.Currently,SonoVue and Sonazoid were the commonly used contrast agents applied to focal liver lesions,the former being a pure blood pool agent and the latter adding a Kupffer phase to liver’s triple-vessel phase,but whether the ultrasonographic feature and application value of the two agents are equivalent has not been reported systemically.This article reviews the progress of the SonoVue and Sonazoid application in terms of their physicochemical properties,the diagnostic and differential diagnostic values in the diagnosis of benign and malignant lesions in the liver,guiding interventional treatment and safety performance.

关 键 词：肝脏局灶性病变 SONOVUE SONAZOID 超声造影 

分 类 号：R445.1[医药卫生—影像医学与核医学] R575[医药卫生—诊断学]